INDEMNIFICATION AGREEMENTIndemnification Agreement • July 28th, 2020 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (“Agreement”) is made as of [l], by and between INHIBRX, INC., a Delaware corporation (the “Company”), and [l] (the “Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • July 28th, 2020 • Inhibrx, Inc. • Biological products, (no disgnostic substances)
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of July 15, 2020 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time, including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and INHIBRX, INC., a Delaware corporation with an office located at 11025 North Torrey Pines Road, Suite 200, La Jolla, CA 92037 (“Borrower”), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties agree as follows:
Option and License AgreementOption and License Agreement • July 28th, 2020 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
This Option and License Agreement (this “Agreement”), effective as of June 9, 2020 (the “Effective Date”), is entered into by and between Inhibrx, Inc., a Delaware corporation (“Inhibrx”), and bluebird bio, Inc., a Delaware corporation (“Licensee”). Inhibrx and Licensee are referred to individually as a “Party” and collectively as the “Parties.”
INHIBRX, INC. AMENDMENT TO CONVERTIBLE PROMISSORY NOTEPurchase Agreement • July 28th, 2020 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
This AMENDMENT (the “Amendment”) to that certain Convertible Promissory Note listed on Schedule A hereto (the “Note”) issued pursuant to the terms of that certain Note Purchase Agreement by and among the Inhibrx, Inc., a Delaware corporation (the “Company”) and DRAGSA 50 LLC (the “Investor”), dated as of May 20, 2019 (the “Purchase Agreement”), is entered into as of April 6, 2020, by and between the Company and the Investor. All capitalized terms used herein without definition shall have the meanings ascribed to them in the Note.
ContractInhibrx, Inc. • July 28th, 2020 • Biological products, (no disgnostic substances) • New York
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
Amendment No. 1 to Amended and Restated Master Services AgreementInhibrx, Inc. • July 28th, 2020 • Biological products, (no disgnostic substances)
This Amendment No. 1 (this “Amendment”) to the Amended and Restated Master Services Agreement by and between Inhibrx, Inc. (f/k/a Inhibrx LP) (“Client”) and WuXi Biologics (Hong Kong) Limited (“Provider”) dated August 28, 2018 (the “Agreement”) is made by and between Client and Provider effective as of December 11, 2019. All capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.
